456 related articles for article (PubMed ID: 27537997)
1. Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: Second of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-Controlled Trials.
Eichenfield LF; Lain T; Frankel EH; Jones TM; Chang-Lin JE; Berk DR; Ruan S; Kaoukhov A
J Drugs Dermatol; 2016 Aug; 15(8):962-9. PubMed ID: 27537997
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: First of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-controlled Trials.
Stein Gold LF; Jarratt MT; Bucko AD; Grekin SK; Berlin JM; Bukhalo M; Weiss JS; Berk DR; Chang-Lin JE; Lin V; Kaoukhov A
J Drugs Dermatol; 2016 May; 15(5):553-61. PubMed ID: 27168264
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, Safety, and Tolerability of Topical Dapsone Gel, 7.5% for Treatment of Acne Vulgaris by Fitzpatrick Skin Phototype.
Taylor SC; Cook-Bolden FE; McMichael A; Downie JB; Rodriguez DA; Alexis AF; Callender VD; Alvandi N
J Drugs Dermatol; 2018 Feb; 17(2):160-167. PubMed ID: 29462223
[TBL] [Abstract][Full Text] [Related]
4. Treatment Response With Once-Daily Topical Dapsone Gel, 7.5% for Acne Vulgaris: Subgroup Analysis of Pooled Data from Two Randomized, Double-Blind Stu.
Draelos ZD; Rodriguez DA; Kempers SE; Bruce S; Peredo MI; Downie J; Chang-Lin JE; Berk DR; Ruan S; Kaoukhov A
J Drugs Dermatol; 2017 Jun; 16(6):591-598. PubMed ID: 28686777
[TBL] [Abstract][Full Text] [Related]
5. Safety and Pharmacokinetics of Once-Daily Dapsone Gel, 7.5% in Patients With Moderate Acne Vulgaris.
Jarratt MT; Jones TM; Chang-Lin JE; Tong W; Berk DR; Lin V; Kaoukhov A
J Drugs Dermatol; 2016 Oct; 15(10):1250-1259. PubMed ID: 27741344
[TBL] [Abstract][Full Text] [Related]
6. Clinical Experience With Once-Daily Dapsone Gel, 7.5% Monotherapy in Patients With Acne Vulgaris.
Stockton TC; Tanghetti EA; Lain E; Zeichner JA; Alvandi N
J Drugs Dermatol; 2018 Jun; 17(6):602-608. PubMed ID: 29879247
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, Safety, and Dermal Tolerability of Dapsone Gel, 7.5% in Patients with Moderate Acne Vulgaris: A Pooled Analysis of Two Phase 3 Trials.
Thiboutot DM; Kircik L; McMichael A; Cook-Bolden FE; Tyring SK; Berk DR; Chang-Lin JE; Lin V; Kaoukhov A
J Clin Aesthet Dermatol; 2016 Oct; 9(10):18-27. PubMed ID: 27847545
[No Abstract] [Full Text] [Related]
8. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris.
Draelos ZD; Carter E; Maloney JM; Elewski B; Poulin Y; Lynde C; Garrett S;
J Am Acad Dermatol; 2007 Mar; 56(3):439.e1-10. PubMed ID: 17208334
[TBL] [Abstract][Full Text] [Related]
9. Novel Tretinoin 0.05% Lotion for the Once-daily Treatment of Moderate-to-Severe Acne Vulgaris in an Adult and Adolescent Female Population.
Kircik LH; Baldwin H; Lain E; Guenin E; Harris S; Bhatt V
J Drugs Dermatol; 2019 Feb; 18(2):178-188. PubMed ID: 30811141
[TBL] [Abstract][Full Text] [Related]
10. The Efficacy and Safety of Topical Dapsone Gel, 5% for the Treatment of Acne Vulgaris in Adult Females With Skin of Color.
Alexis AF; Burgess C; Callender VD; Herzog JL; Roberts WE; Schweiger ES; Stockton TC; Gallagher CJ
J Drugs Dermatol; 2016 Feb; 15(2):197-204. PubMed ID: 26885788
[TBL] [Abstract][Full Text] [Related]
11. Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females.
Tanghetti E; Harper J; Baldwin H; Kircik L; Bai Z; Alvandi N
J Drugs Dermatol; 2018 Nov; 17(11):1192-1198. PubMed ID: 30500139
[TBL] [Abstract][Full Text] [Related]
12. Results of a Phase 2, Randomized,Vehicle-Controlled Study Evaluating the Efficacy,Tolerability, and Safety of Daily or Twice Daily SB204 for the Treatment of Acne Vulgaris.
Eichenfield LF; Gold LS; Nahm WK; Cook-Bolden FE; Pariser DM
J Drugs Dermatol; 2016 Dec; 15(12):1496-15027. PubMed ID: 28095573
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Tolerability of a Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate or Severe Acne Vulgaris in Adult Females.
Harper JC; Baldwin H; Stein Gold L; Guenin E
J Drugs Dermatol; 2019 Nov; 18(11):1147-1154. PubMed ID: 31741360
[TBL] [Abstract][Full Text] [Related]
14. Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females.
Tanghetti E; Harper J; Baldwin H; Kircik L; Bai Z; Alvandi N
J Drugs Dermatol; 2018 Nov; 17(11):1192-1198. PubMed ID: 30500141
[TBL] [Abstract][Full Text] [Related]
15. Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females.
Tanghetti E; Harper J; Baldwin H; Kircik L; Bai Z; Alvandi N
J Drugs Dermatol; 2018 Nov; 17(11):1192-1198. PubMed ID: 30500140
[TBL] [Abstract][Full Text] [Related]
16. Dapsone 7.5% Gel: A Review in Acne Vulgaris.
Al-Salama ZT; Deeks ED
Am J Clin Dermatol; 2017 Feb; 18(1):139-145. PubMed ID: 28005194
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and tolerability of dapsone 5% gel in female vs male patients with facial acne vulgaris: gender as a clinically relevant outcome variable.
Tanghetti E; Harper JC; Oefelein MG
J Drugs Dermatol; 2012 Dec; 11(12):1417-21. PubMed ID: 23377510
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris in adolescents.
Raimer S; Maloney JM; Bourcier M; Wilson D; Papp K; Siegfried E; Garrett S;
Cutis; 2008 Feb; 81(2):171-8. PubMed ID: 18441772
[TBL] [Abstract][Full Text] [Related]
19. Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment.
Lucky AW; Maloney JM; Roberts J; Taylor S; Jones T; Ling M; Garrett S;
J Drugs Dermatol; 2007 Oct; 6(10):981-7. PubMed ID: 17966175
[TBL] [Abstract][Full Text] [Related]
20. Novel Tretinoin 0.05% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in a Hispanic Population.
Cook-Bolden FE; Weinkle SH; Guenin E; Bhatt V
J Drugs Dermatol; 2019 Jan; 18(1):32-38. PubMed ID: 30681791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
